Scottish Equity Partners Announces Investment in Dotmatics
News Nov 02, 2017
SEP is an informatics software provider delivering enterprise solutions tailored to the modern, highly collaborative and mobile scientific environments. Dotmatics provides solutions for pharmaceutical, biotechnology, academia, food and beverage, oil and gas, and agrochemical industries. The funding will enable Dotmatics to continue its investment into product innovation and customer success, as well as to strengthen operations in each of its key geographies.
Dotmatics’ comprehensive solutions include tools for knowledge management, data storage, enterprise querying and reporting, data analysis and visualisation. Headquartered in the UK, Dotmatics is one of the fastest growing global informatics companies and currently employs more than 100 people including chemists, biologists and software engineers across Europe, USA and Asia Pacific.
The investment deal was led by SEP partners Keith Davidson and Jan Rutherford. Keith Davidson said, “Dotmatics is a fast growing and capital efficient SaaS business, with an excellent reputation in the scientific research informatics market. The company has a strong focus on innovation and providing customers with first class scientific solutions and support. We have watched the company expand its customer base significantly over the course of the last few years and look forward to supporting its future growth plans.”
Stephen Gallagher, CEO of Dotmatics, commented, “We have grown rapidly and organically since inception and are pleased to have secured SEP as investors given the firm’s considerable software and health sector experience and their record of scaling companies. The funding will enable us to continue our aggressive trajectory in providing chemistry solutions, further expansion into biologics and increase our investment into customer support through strategic hires in application science product development and professional services.”
In a new study in cells, University of Illinois researchers have adapted CRISPR gene-editing technology to cause the cell’s internal machinery to skip over a small portion of a gene when transcribing it into a template for protein building. This gives researchers a way not only to eliminate a mutated gene sequence, but to influence how the gene is expressed and regulated.